2nd Dec 2021 09:44
genedrive plc
("genedrive" or the "Company")
Grant of Options
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that on 2 December 2021 share options ("Options") were granted to members of its senior management team to acquire a total of 400,000 ordinary shares of 1.5p each ("Ordinary Shares") in the Company under the Company's Share Option Scheme.
The Options have been granted with an exercise price of 31p being equal to the closing price on the day before the grant and vest after a period of three years, subject to certain performance criteria being met through achieving revenue and other financial targets, as well as completing certain strategic projects in the year ending 30 June 2024. The Options are exercisable over the period of 10 years from the date of grant.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||||||||||||||
a. | Name | 1. Alex Mann 2. Jonathan Barber 3. Gino Miele 4. Colleen Phythian
| ||||||||||||||||||||||||
2. | Reason for the notification | |||||||||||||||||||||||||
a. | Position/status | 1. Commercial Director 2. Operations Director 3. R&D Director 4. Director of Quality & Regulation | ||||||||||||||||||||||||
a. | Initial notification /Amendment | Initial notification | ||||||||||||||||||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||||
a. | Name | genedrive plc | ||||||||||||||||||||||||
b. | LEI | 213800ZYODIRZ87Y4K14 | ||||||||||||||||||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||||||||||||||
a. | Description of the Financial instrument, type of instrument Identification code | Options over ordinary shares of 1.5 pence each
GB00B1VKB244 | ||||||||||||||||||||||||
b. | Nature of the transaction | Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 29 November 2017 | ||||||||||||||||||||||||
c. | Price(s) and volume(s) |
| ||||||||||||||||||||||||
d. | Aggregated information Aggregated volume Price
|
N/A
| ||||||||||||||||||||||||
e. | Date of the transaction | 2021-12-02 | ||||||||||||||||||||||||
f. | Place of the transaction | Outside a trading venue | ||||||||||||||||||||||||
For further details please contact:
genedrive plc | +44 (0)161 989 0245 | |
David Budd: CEO / Matthew Fowler: CFO |
| |
| ||
|
| |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 | |
James Steel |
| |
| ||
|
| |
finnCap (Joint Broker) | +44 (0)20 7220 500 | |
Geoff Nash / Kate Bannatyne / Alice Lane | ||
Walbrook PR Ltd (Media Relations & Investor Relations) | +44 (0)20 7933 8780 or [email protected] | |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 | |
Related Shares:
Genedrive